The opiate antagonist, naltrexone, in the treatment of trichotillomania: Results of a double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 134-138

  Grant, Jon E ^a   Odlaug, Brian L ^a,b   Schreiber, Liana R N ^c   Kim, Suck Won ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Hair pulling; Impulsivity; Opioid; Trichotillomania

Indexed keywords

NALTREXONE; PLACEBO;

ADULT; AGED; ARTICLE; BEHAVIOR; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TRICHOTILLOMANIA; YOUNG ADULT;

ADULT; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRICHOTILLOMANIA; YOUNG ADULT;

EID: 84891747409     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000037     Document Type: Article

References (25)

1. Mansueto CS, Rogers KE. Trichotillomania: epidemiology and clinical characteristics. In: Grant JE, Stein DJ, Woods DW, eds. Trichotillomania, Skin Picking, & Other Body-Focused Repetitive Behaviors. Washington, DC: APPI; 2012:3-20.
2. Christenson GAH. The assessment and treatment of trichotillomania. In: Grant JE, Potenza MN, eds. The Oxford Handbook of Impulse Control Disorders. New York, NY: Oxford University Press; 2012:313-333.
3. Grant JE, Odlaug BL, Potenza MN. Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. Harv Rev Psychiatry. 2007;15(2):80-85.
4. Schlosser S, Black DW, Blum N, et al. The demography, phenomenology, and family history of 22 persons with compulsive hair pulling. Ann Clin Psychiatry. 1994;6(3):147-152.
5. Chamberlain SR, Fineberg NA, Blackwell AD, et al. Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am J Psychiatry. 2006;163(7):1282-1284.
6. Li CS, Huang C, Yan P, et al. Neural correlates of impulse control during stop signal inhibition in cocaine-dependent men. Neuropsychopharmacology. 2008;33(8):1798-1806.
7. Dodman NH, Shuster L, White SD, et al. Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs. J Am Vet Med Assoc. 1988;193(7):815-819.
8. White SD. Naltrexone for treatment of acral lick dermatitis in dogs. J Am Vet Med Assoc. 1990;196(7):1073-1076.
9. De Sousa A. An open-label pilot study of naltrexone in childhood-onset trichotillomania. J Child Adolesc Psychopharmacol. 2008;18(1):30-33.
10. Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev. 2010;35(2):129-150.
11. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995.
12. Keuthen NJ, O'Sullivan RL, Ricciardi JN, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. Psychother Psychosom. 1995;64:141-145.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education & Welfare (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976.
14. Hamilton M. The assessment of anxiety states by rating. Br JMed Psychol. 1959;32:50-55.
15. Hamilton M.Arating scale for depression. J NeurolNeurosurg Psychiatry. 1960;23:56-62.
16. Sheehan DV. The Anxiety Disease. New York, NY: Scribner's; 1983.
17. Frisch MB, Cornell J, Villanueva M. Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 1993;4(1):92-101.
18. Owen AM, Roberts AC, Polkey CE, et al. Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1991;29(10):993-1006.
19. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cogn Sci. 2004;8(4):170-177.
20. Grant JE, Kim SW, Potenza MN, et al. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacoogyl (Berl). 2008;200:521-527.
21. Tuominen L, Salo J, Hirvonen J, et al. Temperament trait Harm Avoidance associates with K-opioid receptor availability in frontal cortex: a PET study using [(11)C]carfentanil. Neuroimage. 2012;61(3):670-676
22. Grant JE, Odlaug BL, Chamberlain SR. A cognitive comparison of pathological skin picking and trichotillomania. J Psychiatr Res. 2011;45(12):1634-1638.
23. Rodefer JS, Nguyen TN. Naltrexone reverses age-induced cognitive deficits in rats. Neurobiol Aging. 2008;29(2);309-313.
24. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546-1552.
25. Roy MA, Walsh D, Prescott CA, et al. Biases in the diagnosis of alcoholism by the family history method. Alcohol Clin Exp Res. 1994;18(4):845-851.